Valuation: Nutriband Inc

Market Cap 37.2M 32.52M 29.88M 27.86M 52.83M 3.54B 53.63M 359M 139M 1.74B 140M 137M 6B P/E 2025
-8.39x
P/E 2026 -1.86x
Enterprise Value 32.87M 28.73M 26.41M 24.61M 46.68M 3.13B 47.39M 317M 123M 1.54B 123M 121M 5.3B EV / Sales 2025
41.1x
EV / Sales 2026 26.5x
Free-Float
28.27%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer 35 31/12/2015
Chief Executive Officer 52 -
Director of Finance/CFO 77 01/09/2020
Director TitleAgeSince
Chairman 52 20/01/2022
Director/Board Member 48 30/06/2018
Director/Board Member 38 30/06/2018
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 37.2M
+3.49%+2.32%-28.86%-12.49% 166B
-1.43%+3.32%-5.77%-5.57% 106B
+2.80%+3.33%+1.83%+54.09% 57.69B
+1.33%-0.73%+56.39%+51.86% 53.2B
+0.30%+4.43%-10.83%-40.12% 43.56B
+3.50%+14.35% - - 36.52B
-1.21%+3.79%-14.75%-44.56% 27.49B
+0.55%+5.53%+65.33%-4.37% 25.84B
-9.53%+3.61%-8.42%-3.01% 21.27B
Average +2.60%+4.14%+6.87%-0.52% 59.8B
Weighted average by Cap. +3.31%+3.29%-3.33%+0.12%

Financials

2025 2026
Net sales 2.14M 1.87M 1.72M 1.6M 3.04M 204M 3.08M 20.64M 8.02M 100M 8.03M 7.86M 345M 2.04M 1.78M 1.64M 1.53M 2.89M 194M 2.94M 19.64M 7.64M 95.32M 7.64M 7.48M 328M
Net income -10.48M -9.16M -8.42M -7.85M -14.89M -998M -15.11M -101M -39.3M -491M -39.35M -38.5M -1.69B -8.23M -7.19M -6.61M -6.16M -11.69M -784M -11.87M -79.37M -30.86M -385M -30.89M -30.23M -1.33B
Net Debt -4.13M -3.61M -3.31M -3.09M -5.86M -393M -5.95M -39.79M -15.47M -193M -15.48M -15.15M -665M -4.33M -3.78M -3.48M -3.24M -6.15M -412M -6.24M -41.76M -16.23M -203M -16.25M -15.9M -698M
Logo Nutriband Inc
Nutriband Inc. is engaged in the development of a portfolio of transdermal pharmaceutical products. Its development pipeline consists of transdermal products that are based on proprietary AVERSA abuse-deterrent transdermal technology. Its lead product under development is AVERSA Fentanyl, an abuse deterrent fentanyl transdermal system that combines an approved generic fentanyl patch with its AVERSA abuse deterrent transdermal technology to reduce the abuse and misuse of fentanyl patches. Its development pipeline also includes AVERSA Buprenorphine and AVERSA Methylphenidate. It is developing a portfolio of transdermal pharmaceutical products to deliver already approved drugs or biologics that are typically delivered by injection but with the potential to improve compliance and therapeutic outcomes through transdermal delivery. AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
Employees
-